SOURCE: NanoInk, Inc.

July 19, 2006 17:32 ET

NanoInk® Appoints Keith E. Brauer to Its Board of Directors

SKOKIE, IL -- (MARKET WIRE) -- July 19, 2006 -- NanoInk, Inc. announced today the appointment of Keith E. Brauer, 58, to the Company's Board of Directors. Mr. Brauer is filling the Board seat vacated by Ruff Fant, who recently resigned from the board. The Company and its board thank Mr. Fant for his three years of dedicated service as a director. Including Mr. Brauer, NanoInk has a total of six directors on its board.

Mr. Brauer brings more than 34 years of financial and administrative experience, and significant international finance expertise, to NanoInk's board. Most recently, he served as Guidant Corporation's Vice President, Finance and Chief Financial Officer until Guidant was acquired by Boston Scientific in 2006. Additionally, while at Guidant, he was responsible for information systems, treasury and investor relations.

Prior to Guidant, Mr. Brauer spent 20 years with Eli Lilly and Company, where he held various positions, including Executive Director, International Finance and Chief Accounting Officer; Director of Corporate Affairs; Vice President of Finance and Treasurer for its Physio-Control subsidiary; Controller of its Elizabeth Arden subsidiary; and Coordinator of business planning for its Medical Devices and Diagnostics division. Prior to Lilly, Mr. Brauer was a finance analyst for Ford Motor Company and a member of the Air National Guard.

Additionally, Mr. Brauer currently serves as a member of the Board of Directors and finance committee for Community Hospitals of Indiana, Audit Committee Chair and Member of the Board of Directors of Suros Surgical Systems, Inc., and Endocyte, Inc. He holds a B.S. from Indiana University and an M.B.A. from the University of Michigan.

"NanoInk is committed to attracting the best talent and expertise as we focus on expanding our commercial operations with global customers," said Dr. Cedric Loiret-Bernal, Chief Executive Officer, NanoInk, Inc. "Keith Brauer is a proven and respected international executive who will bring outstanding finance and healthcare industry experience to our dedicated board."

In accepting his appointment, Mr. Brauer said, "I look forward to working with NanoInk's board and management team to build long-term value for the DPN® and Nanoencryption™ technologies. I am excited to have the opportunity to contribute to NanoInk's growth and the Company's commitment to strong corporate governance."

About NanoInk

NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN®, a patented and proprietary nanofabrication technology that allows for unmatched flexibility and accuracy, and also its high-resolution Nanoencryption™ technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair, and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, and the University of Illinois at Urbana-Champaign. For more information on products and services offered by NanoInk, Inc., see

Contact Information